Show simple item record

dc.creatorSwerdloff, R. S.
dc.creatorBremner, William J.
dc.creatorWang, C.
dc.creatorAnawalt, Bradley D.
dc.creatorBerman, N.
dc.creatorSteiner, B.
dc.creatorBagatell, Carrie J.
dc.identifierJ Clin Endocrinol Metab. 1998 Oct;83(10):3527-33
dc.descriptionGnRH antagonists plus testosterone (T) suppress LH and FSH levels and inhibit spermatogenesis to azoospermia or severe oligozoospermia. High-dose T treatment alone has been shown to be an effective male contraceptive (contraceptive efficacy rate of 1.4 per 100 person yr). Combined GnRH antagonist and T induces azoospermia more rapidly and at a higher incidence than T alone; this combination has therefore been proposed as a prototype male contraceptive. However, because GnRH antagonists are expensive to synthesize and difficult to deliver, it would be desirable to rapidly suppress sperm counts to low levels with GnRH antagonist plus T and maintain azoospermia or severe oligozoospermia with T alone. In this study, 15 healthy men (age 21-41 yr) with normal semen analyses were treated with T enanthate (TE) 100 mg im/week plus 10 mg Nal-Glu GnRH antagonist sc daily for 12 weeks to induce azoospermia or severe oligozoospermia. At 12-16 weeks, 10 of 15 subjects had zero sperm counts, and 14 of 15 had sperm counts less than 3 x 10(6)/mL. The 14 who were suppressed on combined treatment were maintained on TE alone (100 mg/week im) for an additional 20 weeks. Thirteen of 14 subjects in the TE alone phase had sperm counts maintained at less than 3 x 10(6)/mL for 20 weeks. Ten remained persistently azoospermic or had sperm concentration of 0.1 x 10(6)/mL once during maintenance. Mean LH and FSH levels in the subjects were suppressed to 0.4+/-0.2 IU/L and 0.5+/-0.2 IU/L in the induction phase, which was maintained in the maintenance phase. The 1 subject who failed to suppress sperm counts during induction had serum LH and FSH reduced to 0.3 and 0.5 IU/L, respectively. The subject who failed to maintenance had LH and FSH suppressed to 1.0 and 0.2 IU/L, respectively, during the induction phase but these rose to 1.6 and 2.1 IU/L, respectively, during maintenance. Failure to suppress or maintain low sperm counts may be related to incomplete suppression of serum LH and FSH levels. We conclude that sperm counts suppressed with GnRH antagonist plus T can be maintained with relatively low dose TE treatment alone. This concept should be explored further in the development of effective, safe, and affordable hormonal male contraceptives.
dc.publisherEndocrine Society
dc.subjectmale contraception
dc.subject5-alpha reductase inhibitors
dc.subjectreifenstein's syndrome
dc.subjectklinefelter's syndrome
dc.subjectResearch Support, U.S. Gov't, P.H.S.
dc.subjectLuteinizing Hormone, blood
dc.subjectResearch Support, U.S. Gov't, Non-P.H.S.
dc.subjectSpermatogenesis, drug effects
dc.subjectContraceptive Agents, Male, adverse effects, pharmacology
dc.subjectHormone Antagonists, adverse effects, pharmacology
dc.subjectResearch Support, Non-U.S. Gov't
dc.subjectTestosterone, adverse effects, analogs & derivatives, blood, pharmacology
dc.subjectLibido, drug effects
dc.subjectFollicle Stimulating Hormone, blood
dc.subjectDipeptides, adverse effects, pharmacology
dc.subjectSexual Behavior, drug effects
dc.subjectGonadorelin, antagonists & inhibitors
dc.titleSuppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record